Adverse Events Module
For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
Adverse Events Module
Event Groups
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Placebo | Placebo: QD for 12 weeks | 0 | None | 1 | 66 | 1 | 66 | View |
| Linaclotide IR 290 μg | Linaclotide IR formulation: 290 μg QD for 12 weeks | 0 | None | 1 | 66 | 10 | 66 | View |
| Linaclotide DR1 30 μg | Linaclotide DR1 30 μg QD for 12 weeks | 0 | None | 0 | 67 | 4 | 67 | View |
| Linaclotide DR1 100 μg | Linaclotide DR1 100 μg QD for 12 weeks | 0 | None | 0 | 67 | 9 | 67 | View |
| Linaclotide DR1 300 μg | Linaclotide DR1 300 μg QD for 12 weeks | 0 | None | 0 | 67 | 8 | 67 | View |
| Linaclotide DR2 30 μg | Linaclotide DR2 30 μg QD for 12 weeks | 0 | None | 0 | 67 | 0 | 67 | View |
| Linaclotide DR2 100 μg | Linaclotide DR2 100 μg QD for 12 weeks | 0 | None | 0 | 66 | 1 | 66 | View |
| Linaclotide DR2 300 μg | Linaclotide DR2 300 μg QD for 12 weeks | 0 | None | 0 | 66 | 2 | 66 | View |